Zacks.com on MSN12h
MRNA Begins Dosing in Pivotal Study on Norovirus VaccineModerna, Inc. MRNA announced the dosing of the first participant in the phase III Nova 301 study, which is evaluating its ...
GlobalData on MSN15h
Moderna doses first subject in Phase III trial of mRNA norovirus vaccine in USUS-based pharmaceutical company Moderna has dosed the first subject in the US in its Phase III Nova 301 clinical trial of its ...
CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first participant in the U.S. has been ...
The trial will evaluate the safety, effectiveness and ability of the shot, dubbed mRNA-1403, to induce an immune response in ...
[10] A Phase 1 trial designed to evaluate the safety, reactogenicity and immunogenicity of a trivalent norovirus vaccinecandidate, mRNA-1403, in participants 18 to 49 years of age and 60 to 80 ...
The seeds of Spanish filmmaker Pedro Almodóvar’s later cinematic work are scattered throughout the pages of “The Last Dream,” ...
Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID combination vaccine for approval in 2024Announces ...
CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first participant in the U.S. has been dosed in the Nova 301 Trial, a pivotal Phase 3 randomized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback